These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30282813)

  • 1. Immune Effector Functions of Human IgG2 Antibodies against EGFR.
    Rösner T; Kahle S; Montenegro F; Matlung HL; Jansen JHM; Evers M; Beurskens F; Leusen JHW; van den Berg TK; Valerius T
    Mol Cancer Ther; 2019 Jan; 18(1):75-88. PubMed ID: 30282813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions.
    Baumann N; Rösner T; Jansen JHM; Chan C; Marie Eichholz K; Klausz K; Winterberg D; Müller K; Humpe A; Burger R; Peipp M; Schewe DM; Kellner C; Leusen JHW; Valerius T
    Cancer Sci; 2021 Aug; 112(8):3029-3040. PubMed ID: 34058788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients.
    Trivedi S; Srivastava RM; Concha-Benavente F; Ferrone S; Garcia-Bates TM; Li J; Ferris RL
    Clin Cancer Res; 2016 Nov; 22(21):5229-5237. PubMed ID: 27217441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab.
    Patel D; Guo X; Ng S; Melchior M; Balderes P; Burtrum D; Persaud K; Luna X; Ludwig DL; Kang X
    Hum Antibodies; 2010; 19(4):89-99. PubMed ID: 21178280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing Neutrophil Cytotoxicity of a Panel of Clinical EGFR Antibodies by Fc Engineering to IgA3.0.
    Chan C; Jansen JHM; Hendriks IST; van der Peet IC; Verdonschot MEL; Passchier EM; Tsioumpekou M; Nederend M; Klomp SA; Valerius T; Peipp M; Leusen JHW; Olofsen PA
    Mol Cancer Ther; 2024 Sep; 23(9):1317-1331. PubMed ID: 38958494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-dependent cellular cytotoxicity in patients on chronic hemodialysis.
    Koch T; Derer S; Staudinger M; Rossen K; Glorius P; Peipp M; Kellner C; Kunzendorf U; Valerius T; Dechant M
    Am J Nephrol; 2013; 38(5):379-87. PubMed ID: 24157422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
    Braster R; O'Toole T; van Egmond M
    Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage.
    Schneider-Merck T; Lammerts van Bueren JJ; Berger S; Rossen K; van Berkel PH; Derer S; Beyer T; Lohse S; Bleeker WK; Peipp M; Parren PW; van de Winkel JG; Valerius T; Dechant M
    J Immunol; 2010 Jan; 184(1):512-20. PubMed ID: 19949082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance.
    Tardito S; Matis S; Zocchi MR; Benelli R; Poggi A
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
    Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
    BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.
    Tintelnot J; Baum N; Schultheiß C; Braig F; Trentmann M; Finter J; Fumey W; Bannas P; Fehse B; Riecken K; Schuetze K; Bokemeyer C; Rösner T; Valerius T; Peipp M; Koch-Nolte F; Binder M
    Mol Cancer Ther; 2019 Apr; 18(4):823-833. PubMed ID: 30824613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
    Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
    Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).
    Correale P; Marra M; Remondo C; Migali C; Misso G; Arcuri FP; Del Vecchio MT; Carducci A; Loiacono L; Tassone P; Abbruzzese A; Tagliaferri P; Caraglia M
    Eur J Cancer; 2010 Jun; 46(9):1703-11. PubMed ID: 20399639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of somatic mutations on EGFR interaction with anti-EGFR monoclonal antibodies: Implication for acquired resistance.
    Tabasinezhad M; Omidinia E; Talebkhan Y; Omrani MD; Mahboudi F; Ghaedi H; Wenzel W
    Proteins; 2020 Jan; 88(1):3-14. PubMed ID: 31228284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity.
    Derer S; Glorius P; Schlaeth M; Lohse S; Klausz K; Muchhal U; Desjarlais JR; Humpe A; Valerius T; Peipp M
    MAbs; 2014; 6(2):409-21. PubMed ID: 24492248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.
    Gerdes CA; Nicolini VG; Herter S; van Puijenbroek E; Lang S; Roemmele M; Moessner E; Freytag O; Friess T; Ries CH; Bossenmaier B; Mueller HJ; Umaña P
    Clin Cancer Res; 2013 Mar; 19(5):1126-38. PubMed ID: 23209031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgG1 anti-epidermal growth factor receptor antibodies induce CD8-dependent antitumor activity.
    Kubach J; Hubo M; Amendt C; Stroh C; Jonuleit H
    Int J Cancer; 2015 Feb; 136(4):821-30. PubMed ID: 24947844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
    Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK
    Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells.
    Kol A; Terwisscha van Scheltinga A; Pool M; Gerdes C; de Vries E; de Jong S
    Oncotarget; 2017 Jul; 8(28):45432-45446. PubMed ID: 28467975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.